Dr Martens said it made “good progress” on its turnaround efforts as third quarter trading was “as expected”.
The footwear retailer reported a 3% rise in group sales on a constant currency basis to £267m in the 13 weeks to 29 December, up from £260m.
Its direct-to-consumer (DTC) channel edged up 1%, which it said was a result of a 2% rise in ecommerce, which offset the 1% dip in retail revenue.
Wholesale revenue jumped 9% during the period, performing in line with expectations despite a single-digit dip in its Americas division.
Related Story
Dr Martens reported its DTC sales for its Europe, Middle East and Africa arm dropped 5%, which it blamed on the “deep promotional nature of several markets, especially in December”.
Following its performance over peak, the retailer confirmed its full-year outlook remained unchanged and that it is on track to achieve its objectives for the year.
Dr Martens chief executive Ije Nwokorie said: “The global relevance of our iconic brand, the strength of our product line and the passionate commitment of our team give me great confidence for FY25 and beyond.
“Our Q3 trading was as expected and our outlook for FY25 remains unchanged. We have made good progress against our objective of turning around our USA performance, with USA DTC in positive growth in Q3.
“We continue to actively manage our costs and are on track to meet our inventory reduction target for FY25. The team and I are squarely focused on returning the business to sustainable and profitable growth.”
Click here to sign up to Retail Gazette‘s free daily email newsletter
